Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics

  title={Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics},
  author={Graham Lappin and Lloyd Stevens},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  pages={1021 - 1033}
  • G. Lappin, L. Stevens
  • Published 1 August 2008
  • Biology, Medicine
  • Expert Opinion on Drug Metabolism & Toxicology
Background: Accelerator mass spectrometry (AMS) is a sensitive isotope ratio technique used in drug development that allows for small levels of 14C-drug to be administered to humans, thereby removing regulatory hurdles associated with radiotracer studies. AMS uses innovative study designs to obtain pharmacokinetic and metabolism data. Objective: This review addresses the metabolism and pharmacokinetics relevant to cases where therapeutic drug concentrations are achieved in humans. Methods: The… 

Early human ADME using microdoses and microtracers: bioanalytical considerations.

Quantitative assessment of metabolites of drug candidates in early-phase clinical development presents an analytical challenge when methods, standards and assays are not yet available. Radioisotopic

Microdose Study of 14C‐Acetaminophen With Accelerator Mass Spectrometry to Examine Pharmacokinetics of Parent Drug and Metabolites in Healthy Subjects

Microdosing of 14C‐labeled drug followed by AMS is a powerful tool that can be used in the early phase of drug development for pharmacokinetic analysis of drugs and their metabolites and for detecting the formation of active metabolites in humans.

The early estimation of circulating drug metabolites in humans

  • D. Luffer-Atlas
  • Biology, Medicine
    Expert opinion on drug metabolism & toxicology
  • 2012
This review provides context for ‘why' human circulating metabolites must be qualified for safety in animals and a detailed overview is presented concerning ‘where,' ‘how' and ‘when' to conduct these assessments during drug development.

Pharmacokinetics II: 14C-Labelled Microdosing in Assessing Drug Pharmacokinetics at Phase 0

Inclusion of a 14C isotopic tracer into the molecule enables sensitive AMS analysis to be used as well as obtaining an early indication of the drug’s metabolism in humans.

Practical and efficient strategy for evaluating oral absolute bioavailability with an intravenous microdose of a stable isotopically-labeled drug using a selected reaction monitoring mass spectrometry assay.

This strategy significantly improves bioanalytical data quality and saves time, costs, and resources by avoiding a traditional absolute bioavailability study or the newer approach of microdoses of a radio-microtracer measured by accelerator mass spectrometry.

Direct radiocarbon analysis of exhaled air

Pharmacokinetic properties of organic substances in humans can be followed by isotopic labeling. For sub-milligram amounts, 14C becomes the preferable isotope and Accelerator Mass Spectrometry (AMS)

Accelerator mass spectrometry best practices for accuracy and precision in bioanalytical (14)C measurements.

This review seeks to address a bioanalytical audience, who should know that high accuracy data of physiochemical processes within living human subjects are available, as long as a (14)C quantitation can be made indicative of the physiochemistry of interest.

Approaches for the rapid identification of drug metabolites in early clinical studies.

This review provides an overview of modern approaches for characterizing drug metabolites in these early clinical studies, and concludes with a forward-looking perspective on how this progression may continue into the next decade.

Microdosing: Pharmacokinetic and Metabolism Data Early in the Drug Development Process

The concept of microdosing has been around for over a decade and is now finding application in drug development, with insights to the reasons of non-linearity beginning to be understood.



Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research.

The ability to use very low chemical doses, low radiological doses, small samples and conduct multiple dose studies may help move drug candidates into humans faster and safer than before.

The use of accelerator mass spectrometry to obtain early human ADME/PK data

Accelerator mass spectrometry (AMS), a technology new to the pharmaceutical industry, is an ultrasensitive technique for measuring tracers such as 14C that enables other studies such as absolute bioavailability to be conducted earlier if required.

Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry

A new drug development concept which relies on the ultrasensitivity of AMS known as human microdosing (Phase 0) is being used to obtain early human metabolism information of candidate drugs arising out of discovery.

The Application of Accelerator Mass Spectrometry to Absolute Bioavailability Studies in Humans: Simultaneous Administration of an Intravenous Microdose of 14C‐Nelfinavir Mesylate Solution and Oral Nelfinavir to Healthy Volunteers

The moderate bioavailability of nelfinavir was due to significant first‐pass metabolism rather than low absorption, limiting the potential of formulation improvement to decrease pill burden.


It is demonstrated that pharmacokinetics can be readily characterized by LC-MS/MS at a microdose of 1 μg/kg for these molecules in rats, and, hence, LC- MS/MS should be adequate in human microdosing studies.

The use of isotopes in the determination of absolute bioavailability of drugs in humans

This work has shown that isotopic labelling not only allows for the accurate and efficient determination of absolute bioavailability, but can also provide information on first-pass effects and other pharmacokinetic parameters.

Radiotracers in drug development

This is the only comprehensive, interdisciplinary resource covering the how-tos of employing radiotracers in drug development, and provides detailed information on how the science is relevant to the registration process.

Microdosing Assessment to Evaluate Pharmacokinetics and Drug Metabolism in Rats Using Liquid Chromatography-Tandem Mass Spectrometry

This study has shown the promise of sensitive LC-MS/MS method to support microdose pharmacokinetics and drug metabolism studies in human.

Accelerator mass spectrometry in pharmaceutical research and development--a new ultrasensitive analytical method for isotope measurement.

The exquisite sensitivity of AMS analysis means that much lower amounts of 14C can be used than for conventional counting methods, which makes it easier to use 14C for in vitro, preclinical and clinical research programmes.